Patent intelligence · US
US 10173985
Aminoindazole derivatives as sodium channel inhibitors
Aminoindazole derivatives as sodium channel inhibitors
Patent details — US 10173985
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 8, 2019
- Expiration
- Jan 3, 2039
- Applicant
- Almirall, S.A.
- Claims
- 20
- CPC classes
- A61K, A61K31/416, A61K31/437, A61K31/4439
Quick answer
US 10173985 (Aminoindazole derivatives as sodium channel inhibitors) is held by Almirall, S.A.. Status: granted. Granted Jan 8, 2019. Expires Jan 3, 2039 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Almirall, S.A.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/416, A61K31/437, A61K31/4439, A61K31/454, A61K31/4545
More from Almirall, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 10173985?
US 10173985 (Aminoindazole derivatives as sodium channel inhibitors) is held by Almirall, S.A.. Status: granted. Granted Jan 8, 2019. Expires Jan 3, 2039 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10173985?
Almirall, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 10173985 expire?
Our index shows an expiration date of Jan 3, 2039 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.